The Google contact lens will be in humans next year, Novartis chief says
No diabetes yet. Instead, presbyopia.
What will it take to shift the 80-20 rule for healthcare?
In healthcare, we have our own Pareto principle: 80% of healthcare costs are attributed to 20% of the populace: the chronically ill.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Morning Read: Novo Nordisk acquires 2 U.S. biotechs targeting diabetes, insurers get greenlight on double digit rate hikes
Novo Nordisk has acquired Indiana-based Calibrium LLC and MB2 LLC, which are developing drugs for diabetes and metabolic diseases, some health insurers are dramatically increasing rates.
Can deconstructing the biological clock help treat diabetes and cancer?
Rhode Island biopharma company VeroScience aims to understand Circadian rhythms, harnessing the biological clock to treat diseases like type 2 diabetes and cancer.
69% of doctors believe parents are either completely or mostly to blame for childhood obesity
When it comes to childhood obesity, who is to blame?
Elcelyx: Taking the GI, kidney distress out of diabetes drug metformin
A next-gen form of ubiquitous diabetes drug metformin could have some serious impact on the type 2 diabetes market - as evidenced in some promising Phase 2 data from San Diego startup Elcelyx.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Intarcia’s type 2 diabetes implant more effective than top-seller Januvia, could improve patient adherence
Top-selling diabetes drug Januvia may get a run for its money: Boston-based Intarcia Therapeutics released Phase 3 results saying its implantable device is more effective in treating diabetes and obesity than Januvia.
Why Google and DexCom will change the Type 2 diabetes market
Google and DexCom are building a better glucose sensor; this will impact the Type 2 diabetes market and help usher in a new era of artificial pancreases.
Google, DexCom to lower cost, size of continuous glucose monitors
DexCom has partnered with Google's life sciences arm to build a next-gen continuous glucose monitor. The new devices, expected out in the next 2-3 years, will be much smaller and cheaper, the companies say.
Morning Read: Sanofi and Evotec partner to end need for insulin injections for diabetes
Sanofi and Evotec have entered a collaboration to develop therapeutics to end or reduce the need for insulin injections for diabetes.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Study: A new platform to diagnose, treat type 1 diabetes complications?
Joslin Diabetes Center researchers have found an exciting new mechanism that could lead to a new generation of diagnostics and therapeutics for complications of type 1 diabetes.
Infographic: Diabetes drug costs rising at staggering rate
Diabetes drug costs are rising at a staggering rate, though it seems to stem more from competitor price-matching than from providing paradigm-shifting drugs. This ACHP infographic sums things up nicely.
You could soon get a health assessment by simply checking out your reflection in a smart mirror
What does your face say about your risk for disease?
The evolution of wound care and the high stakes of wound treatment
Approximately 6.5 million Americans are affected by advanced non-healing wounds each year.
Survey: Employer wellness programs reveal undiagnosed chronic conditions (Updated)
About 8.1 million people have undiagnosed diabetes, accounting for more than one-quarter of the diabetes population, according to the CDC.